Measuring absorbed dose for i-CAT CBCT examinations in child, adolescent and adult phantoms

OBJECTIVES

Design and construct child and adolescent head phantoms to measure the absorbed doses imparted during dental CBCT and compare with the absorbed dose measured in an adult phantom.

METHODS

A child phantom was developed to represent the smallest patients receiving CBCT, usually for craniofacial developmental concerns, and an adolescent phantom was developed to represent healthy orthodontic patients. Absorbed doses were measured using a thimble ionization chamber for the custom-built child and adolescent phantoms and compared with measurements using a commercially available adult phantom. Imaging was performed with an i-CAT Next Generation (Imaging Sciences International, Hatfield, PA) CBCT using two different fields of view covering the craniofacial complex (130 mm high) or maxilla/mandible (60 mm high).

RESULTS

Measured absorbed doses varied depending on the location of the ionization chamber within the phantoms. For CBCT images obtained using the same protocol for all phantoms, the highest absorbed dose was measured in all locations of the small child phantom. The lowest absorbed dose was measured in the adult phantom.

CONCLUSIONS

Images were obtained with the same protocol for the adult, adolescent and child phantoms. A consistent trend was observed with the highest absorbed dose being measured in the smallest phantom (child), while the lowest absorbed dose was measured in the largest phantom (adult). This study demonstrates the importance of child-sizing the dose by using dedicated paediatric protocols optimized for the imaging task, which is critical as children are more sensitive to harmful effects of radiation and have a longer life-span post-irradiation for radiation-induced symptoms to develop than do adults.

Abstract P6-06-25: Usefulness of pretreatment NLR as prognostic factor of late recurrence, 5-year after primary treatment

Background

Prognostic factor and predictive factors are well established in early-stage breast cancer, but less is known about recurrence, especially 5-year after primary treatment. While mortality of breast cancer is from organic dysfunction with metastatic disease, not from the diseased breast itself, still we do not have adequate information about metastatic disease as we do about primary breast cancer itself.

The aim of this study is to investigate of usefulness of pretreatment NLR(neutrophil to lymphocyte ratio) as prognostic factor that can tell risk of recurrence 5- year after primary treatment.

Patients and methods

A retrospective review of invasive breast cancer patients surgically resected between January 2001 and December 2007. Exclusion criteria were as followings: patients with recurrence or death within 5yrs.

Results

A total of 301 patients were included and 13 patients experienced with recurrence after 5 years.

Table 1. Patients' characteristics Total (n = 301) N (%)Age*48.8(±11.4)Age ≤3525(8.3)35< ≤50165(54.8)50<111(36.9)Histology Ductal270(89.7)Lobular7(2.3)Others24(8.0)Tumor size (cm)*2.73(±1.64)T stage T1126(41.9)T2158(52.5)T317(5.6)N stage N0199(66.1)N167(22.3)N220(6.6)N311(3.7)unknown4(1.3)Histologic grade I72(23.9)II110(36.5)III70 (23.3)unknown49(16.3)Estrogen receptor Negative111(36.9)Positive185(61.5)unknown5(1.6)Progesterone receptor Negative129(42.9)Positive167(55.5)Unknown5(1.6)HER-2 Negative196(65.1)Positive98(32.6)unknown7(2.3)Molecular subtype Luminal A136(45.2)Luminal B66(21.9)HER-2 enriched32(10.6)Triple negative60(20.0)unknown7(2.3)Late recur Yes13(4.3)No288(95.7)*mean±SD

Overall average of NLR value was 2.16, median value was 1.83. The average NLR were 2.80±1.68 in patients with recurrences occurred after 5 years and 2.13±1.15 in patients without recurrence. The NLR cutoff value of 1.83 was determined by median value.

In 1.83≤NLR group has a higher incidence of recurrence after 5 years compared with NLR<1.83 group (8yr DFS 99.2% vs. 93.3%, p = 0.021). Especially in luminal A(ER (+) or PR (+), HER-2(-)), 1.83≤NLR group has a higher incidence of recurrence after 5 years compared with NLR<1.83 group (8yr DFS 100% vs. 87.0%, p = 0.015).

Conclusion

We found that pretreatment NLR is associated with late recurrence that occurs after five years. And we suggest that NLR could be used as one of the prognostic factor that can tell about late recurrence, 5-year after primary treatment.

Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P6-06-25.